Trademark Overview
On Wednesday, June 24, 2026, a trademark application was filed for TAYZELGA with the United States Patent and Trademark Office. The USPTO has given the TAYZELGA trademark a serial number of 99903790. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Wednesday, June 24, 2026. This trademark is owned by Bristol-Myers Squibb Company. The TAYZELGA trademark is filed in the Pharmaceutical Products category with the following description:
Antivirals; Antibodies for medical purposes; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes; Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, autoimmune diseases, solid organ transplant rejection, autoinflammatory diseases, blood diseases, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, Alzheimer’s disease, autism spectrum disorder, and musculoskeletal and skin diseases; Biological preparations for the treatment of cancer
